Revenue Summary Product sales in the fourth quarter of fiscal 2010 grew to $117.6 million, up 44% as compared to the fourth quarter of fiscal 2009. For the full year 2010, product sales increased 32% from full year 2009, to $434.8 million. Fourth quarter and full year 2010 growth was attributable to our sales of branded consumer health products resulting from our acquisition of Amerifit in 2010, as well as increased sales of our nutritional ingredients in both the infant formula and non-infant formula markets. Fourth quarter infant formula sales growth resulted primarily from increased sales of ARA and DHA for use in international markets and, to a lesser extent, from certain non-recurring stocking orders in the United States.
A breakdown of product sales by market for the fourth quarter and fiscal year periods (in thousands) follows: Three months ended October 31,Twelve months endedOctober 31,20102009% incr (decr)20102009% incr(decr)Nutritional ingredients:Infant formula
11%Food and beverage3,7852,414
59%Pregnancy and nursing, nutritional supplements and animal nutrition 9,6328,219
22%Shipping charges 765557
29%Total nutritional ingredients94,52981,560
14%Branded consumer health products23,075—
(31%) Total product sales
32%Contract manufacturing and services revenue totaled $1.5 million and $15.3 million for the fourth quarter and full year 2010, respectively, of which $1.0 million and $4.1 million, resp
|SOURCE Martek Biosciences Corporation|
Copyright©2010 PR Newswire.
All rights reserved